SNDX Stock Forecast: Syndax Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Syndax Pharmaceuticals, Inc. is $31. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 58 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Syndax Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SNDX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $38 → $36 |
| 13 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $38 |
| 21 Aug 2026 | UBS | Maintains | Buy | $37 → $33 |
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | $44 → $40 |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $38 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 12 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 22 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2026 | UBS | Maintains | Buy | — |
| 1 May 2026 | Barclays | Maintains | Overweight | — |
| 1 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 31 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 30 Mar 2026 | Jefferies | Assumes | Buy | $48 → $40 |
| 9 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 2 Mar 2026 | Citigroup | Maintains | Buy | — |
| 27 Jan 2026 | Mizuho | Maintains | Outperform | $410 → $600 |
| 9 Dec 2025 | BTIG | Reiterates | Buy | — |
| 24 Nov 2025 | Barclays | Maintains | Overweight | — |
| 12 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 4 Nov 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SNDX.
This page is one stock. Monday covers all of them.
SNDX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SNDX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Syndax Pharmaceuticals, Inc. returned −48.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SNDX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.7×
- Price / book
- 51.4×
- EV / EBITDA
- —
Cheaper than 40% of US stocks
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 95.6%
- Operating margin
- −61.7%
- Net margin
- —
Higher than 98% of US stocks
Higher than 17% of US stocks
- Return on equity
- −426.4%
- Return on assets
- −17.9%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Syndax Pharmaceuticals, Inc. has a market value of $785.0M and an enterprise value of $937.2M.
Revenue in the twelve months to 30 June 2026: $252.3M. The latest quarter grew 91.8% year on year.
Net income over the same four quarters: −$220.8M, a −87.5% net margin.
Diluted earnings per share, trailing twelve months: −$2.51.
Free cash flow in the twelve months to 30 June 2026: −$220.9M.
Syndax Pharmaceuticals, Inc. employs 298 people — $846K of revenue per employee.
Data provided by Twelve Data
SNDX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SNDX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Syndax Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SNDX
What is the SNDX stock price forecast for 2026-2027?
The median 12-month analyst price target for Syndax Pharmaceuticals, Inc. is $31, with estimates ranging from $17 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SNDX stock a buy right now?
Of the 12 analysts covering Syndax Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Syndax Pharmaceuticals, Inc. 58 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SNDX?
As at 21 Nov 2026, Syndax Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
Will SNDX stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts is $31, and Ticker Nerd's factor model ranks Syndax Pharmaceuticals, Inc. 58 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SNDX stock forecast for 2030?
No analyst covering Syndax Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $57 over the next 12 months.
How has SNDX stock performed over the past year?
Syndax Pharmaceuticals, Inc. returned -48.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Syndax Pharmaceuticals, Inc. do?
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease. The company’s work spans research, regulatory advancement, and commercial execution, combining clinical development with product launch and market support. Syndax Pharmaceuticals also collaborates with partners to broaden access to its therapies and strengthen its presence in oncology and related specialty care markets. Headquartered in New York, New York, Syndax Pharmaceuticals, Inc. plays a role in advancing targeted treatment options for patients with high unmet medical needs.
CEO Mr. Michael A. Metzger M.B.A. · 298 employees · United States · https://syndax.com